How FDA treats drug repurposing for a new indication when prior Phase 2 data already exists

When a sponsor wants to move an existing drug into a new indication and already holds (or can point to) earlier clinical data, FDA does not treat that development program as if it were starting from zero. The agency has a set of well-worn mechanisms for crediting prior evidence: the 505(b)(2) application pathway, efficacy supplements to an approved NDA, and the "single adequate and well-controlled study plus confirmatory evidence" standard for substantial evidence of effectiveness. In each, earlier-phase or externally generated data can carry real weight, but FDA still requires a defensible scientific bridge from the old data to the new use, and it independently reviews effectiveness and safety for that specific indication.

The 505(b)(2) pathway: relying on data the applicant did not generate

The clearest statutory vehicle for repurposing is the 505(b)(2) NDA, which lets an application rely on FDA's prior finding of safety and effectiveness for a listed drug, on published literature, or on an OTC monograph, rather than requiring the applicant to generate all of the underlying evidence itself ^{119120122123124125126127128129132133134135136138139140141142}. In FDA's own review language, the data an applicant may lean on span clinical data, nonclinical and toxicology data, clinical pharmacology, and the indications, dosing, warnings, and clinical studies drawn from prior approvals or the literature ^123132136.

Earlier-phase and supportive studies feed directly into that reliance package. FDA describes acceptable inputs including comparative bioavailability/bioequivalence studies against the listed drug, standalone PK/BA studies, PK/PD data, comparative physicochemical testing or bioassay, bridging toxicology, and clinical data such as immunogenicity studies, as well as literature-based controlled studies and case reports where scientifically relevant ^{119120121124125126127128132133134136138140141142}.

What FDA insists on is a bridge. For reliance on a listed drug, the bridge must show sufficient similarity between the proposed product and the listed drug, or otherwise establish an adequate basis for relying on FDA's prior finding ^{119120121122124127128129132134135136138139140141142}. Bridging is often a BA/BE study, but FDA has also accepted comparative physicochemical tests, bioassay, preclinical data, PK/PD data, or other scientific rationale ^{119120124132136138140141}. For reliance on the literature, the "bridge" is an explanation of why the cited literature is scientifically sound and relevant to the proposed product, and where the formulation studied differs from the proposed product, FDA has accepted a PK/exposure bridge or a historical cross-study bioavailability comparison ^{119120121128129130131132133134135136137140141}.

Industry commentary frames this the same way. RAPS reports that 505(b)(2) exists precisely so sponsors can rely on data they did not generate, including published literature or FDA's prior findings, to avoid duplicating what is already known, and that it commonly supports a new dose, formulation, route, strength, combination, or a new indication, with the amount of new evidence scaled to what actually changed ⁵¹⁵³. DIA Global Forum characterizes 505(b)(2) as well suited to changing an approved drug's indication, dosage form, regimen, strength, or route without repeating all nonclinical and clinical studies, with reliance anchored primarily to the FDA-approved labeling of the reference listed drug plus new data specific to the new indication ²⁵.

New indication for an already-approved active moiety

Where the active moiety is already approved, FDA still treats a new-use application as a distinct effectiveness question rather than a formality. Prior approval of the moiety does not by itself resolve the new indication; FDA continues to assess whether the proposed use is genuinely new and whether new clinical work supports it ^{3133343536373839414345464748}. The agency's exclusivity analysis illustrates the point: a sponsor can seek new-indication exclusivity based on new clinical studies even when the moiety was approved earlier, as when a supplement's pivotal study was found "new and essential for approval" despite the product containing already-approved active moieties ⁴⁶, or when a supplement requested exclusivity for both a "new formulation" and a "new indication" for a previously approved moiety ³⁵.

For efficacy supplements that add an indication to an approved NDA, FDA's practice is to treat the supplement's new clinical data as the primary basis for the new use while still drawing on the product's existing evidence base and development history where relevant. FDA has, for example, credited dosing information and bioequivalence conclusions carried over from the original NDA and prior clinical pharmacology reviews, and accepted dose modifications consistent with earlier indications supported by dedicated PK trials ⁶⁰⁷⁸. A filing review confirms the general expectation that an efficacy supplement must contain clinical data supporting the additional indication, new dose, or new patient population, which signals that the new use is judged on its own supporting data but not in isolation from the drug's prior record ⁷⁹.

Prior Phase 2 data as confirmatory evidence

The mechanism most directly relevant to "prior Phase 2 data already exists" is FDA's acceptance of a single adequate and well-controlled trial supplemented by confirmatory evidence, where earlier studies can serve as that confirmatory evidence. FDA's reviews show this repeatedly, typically in serious or rare diseases with unmet need where a second pivotal trial would be impractical or ethically difficult ^24791315.

The trofinetide (DAYBUE) review is the cleanest example of an earlier-phase study functioning as confirmatory evidence: FDA accepted the pivotal Study 003 supported by confirmatory evidence from Study 002, an exploratory dose-finding study with nominally significant results and supportive exposure-response analyses ³. Other reviews follow the same logic with different confirmatory sources: nusinersen (SPINRAZA) relied on the pivotal CS3B plus confirmatory evidence from the earlier open-label CS3A ⁹; ropeginterferon alfa-2b (BESREMI) and omaveloxolone (SKYCLARYS) drew confirmatory support from pharmacodynamic biomarkers and natural-history or open-label extension comparisons ⁵⁸; foscarbidopa/foslevodopa (VYALEV) leaned on data from an established product in a similar population and a known mechanism ¹⁹; and tetrabenazine (XENAZINE) and edaravone-class considerations in the RELYVRIO ALS review illustrate the same single-study-plus-confirmation reasoning ¹².

FDA's articulated standard is that confirmatory evidence must substantiate the single trial, with the character and strength required scaled to the robustness of that trial and the clinical context ^351012192024. Acceptable confirmatory sources across these reviews include other clinical studies (including related or open-label extension data), mechanistic and pharmacodynamic evidence, biomarker data, natural-history or historical-control data, evidence from other members of the same pharmacologic class, and in some cases expanded-access or real-world evidence ^{356891219202122}. FDA prefers the confirmatory evidence to be independent of the pivotal trial where possible, and treats it as more persuasive when it is ⁵⁶. In practical terms, a well-conducted prior Phase 2 study is exactly the kind of independent, mechanistically coherent dataset that can anchor this pathway.

What FDA still expects

Prior data shorten the path; they do not remove FDA's independent review of the new indication. Even in repurposing contexts where safety is well established, FDA continues to request a justified bridge and, frequently, additional data. DIA notes that although several COVID-19 emergency use authorizations went to repurposed, previously approved drugs, FDA still requested substantial nonclinical data and bridging clinical studies to support the new therapeutic labeling, and recommended early pre-IND engagement to align on expectations ²⁵. FDA has separately signaled openness to borrowing external and prior data in structured ways, including Bayesian approaches that borrow information across trials, disease subtypes, related diseases, product classes, or populations, with draft guidance emphasizing relevance, data quality, pre-specification, and patient-level data ²⁶. The published literature reaches the same conclusion: repurposing reduces development time and risk because human PK and safety data already exist, but the new indication still generally requires clinical validation, and expedited handling is most available for serious conditions where preliminary evidence suggests a substantial improvement over available therapy ^{81828395102104}.

FDA's evolving posture on repurposing

FDA's institutional interest in repurposing has grown. RAPS reports that in a May 2026 request for input, FDA identified three repurposing scenarios it wants to facilitate: cases where existing data may already support a new use, cases with promising preliminary clinical data from observational studies, and cases supported by preclinical findings including AI/ML outputs, noting that repurposing can speed access by leveraging existing knowledge, including a drug's established safety profile ⁵⁰. That posture is consistent with FDA's broader willingness to use prior or external data elsewhere, such as accepting real-world data to expand palbociclib's (Ibrance) indication to men and using extrapolation from existing clinical data to support pediatric device indications ⁵⁶⁵⁸.

Bottom line for regulatory strategy

For a repurposing program with prior Phase 2 data in hand, three FDA mechanisms are in play, often in combination. The 505(b)(2) pathway lets the application rely on FDA's prior findings and published literature, provided a scientific bridge (frequently PK/BE, sometimes a literature or exposure bridge) connects the relied-upon data to the proposed product ^{119120121124128132136}. An efficacy supplement carries forward the approved product's development history while requiring clinical data specific to the new indication ⁶⁰⁷⁸⁷⁹. And where a second pivotal trial is impractical, a single adequate and well-controlled trial plus confirmatory evidence can meet the substantial-evidence standard, with a prior Phase 2 study among the strongest forms of independent confirmatory evidence FDA has accepted ³⁵⁹¹⁹. In every route, the recurring theme in FDA's reviews is that prior data lower the evidentiary burden but do not eliminate an independent, indication-specific assessment of effectiveness and safety, and that early engagement with the review division to agree on the bridge and the confirmatory package is what determines whether the strategy succeeds.